Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edratide - XTL Biopharmaceuticals

Drug Profile

Edratide - XTL Biopharmaceuticals

Alternative Names: hCDR1; TV-4710

Latest Information Update: 01 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Teva Pharmaceutical Industries; XTL Biopharmaceuticals
  • Class Peptides
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Sjogren's syndrome

Most Recent Events

  • 27 Nov 2017 XTL Biopharmaceuticals plans a phase II trial for Systemic lupus erythematosus
  • 12 Sep 2017 XTL Biopharmaceuticals files for a third patent application with the US Patent and Trademark Office (USPTO) for edratide in USA
  • 16 Jun 2017 Preclinical trials in Sjogren's syndrome in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top